Keyword :
Select Report Type :
Select Industry :
Select Sector :
Select Category :
Select Geography :

Search Results

Report Title
Price
Single User price :$3,007 Add To Cart
Enterprise Price :$6,014 Add To Cart
Global Corporate Price :$18,021 Add To Cart

China is the capital of diabetes of the world with 100 million diabetics. Further the market is estimated to grow many folds as the large proportion of the population is pre-diabetic and which may join the pool in near future. The China Diabetes Management Devices market comprises continuous glucose monitors (CGM), SMBG (Self-monitoring blood glucose meters), manual insulin delivery products, glucose test strips, lancets, syringes, insulin pens and insulin pumps.

Growth of diabetes market in China is driven by high prevalence of diabetes among the aging population, increased life expectancy, surge in sedentary life style, unhealthy diet, high stress levels and increased disposable income. Also, to a large extent the market in terms of volume is boosted by low priced local products which make the treatment affordable and the adoption of new technology products such as insulin pump and CGM in hospital segment and insulin delivery products as well SMBG in home care segment.

 ‘China Diabetes Management Devices – Market Trends, Forecast and competitive Landscape, 2007 – 2020’, a market intelligence report recently published by ABMRG, covers most of the diabetes management and diagnostic devices. It provides historical and statistically refined forecast data for the segments covered.

 It not only puts forth a detailed overview of historical trends and forecasts (2007-2020), the annualized trends for sales in terms of value and volume, market growth, pricing (Average Selling Price or ASP), competitive landscape and market share, but offers a cross-category comparison, market drivers, market restrains and challenges. In addition, it presents an inclusive account of global industry developments for the past two years, including M&As, partnerships, clinical studies, pipeline, product approvals and launches, recalls and litigations, market dynamics and market drivers and restrains.

The key players in this market are Abbott Laboratories (NYSE: ABT), ARKRAY INC., B. Braun Melsungen AG, Becton, Dickinson and Company (NYSE: BDX), F. Hoffmann-La Roche Ltd (ROG: SIX), Johnson & Johnson (NYSE: JNJ), Lifescan, Inc., Medtronic, Inc. (NYSE: MDT), Novo Nordisk A/S (Copenhagen: NOVOb.CO #Reuters; NYSE: NVO), San Meditech (Huzhou) Co. Ltd, Terumo CORPORATION (TSE: 4543).

Why one should buy this report

The report can be instrumental in making strategic decisions pertaining to:

 

ASEAN and Oceania Respiratory Devices and Diagnostics Market Through 2021   $14,600
  • Language: English | #Pages: 254 | Published: May-2015 | Region: Global
Single User price :$14,600 Add To Cart
Enterprise Price :$17,300 Add To Cart
Global Corporate Price :$22,700 Add To Cart

Oceania & ASEAN Respiratory Market to Boost APAC Region Owing to Rising Chronic Respiratory Diseases - Asthma & COPD

 

The only report on ASEAN respiratory devices with a detailed analysis of:

- Hospitals and retail channels

- Respiratory equipment—therapeutic, monitoring and diagnostic

- Markets such as Indonesia, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam as well as Australia, New Zealand and Bangladesh

http://www.abmrg.com/ASEAN-and-Oceania-Respiratory-Devices-and-Diagnostics-Market-Through-2021.html

The respiratory devices and diagnostics market comprises diagnostic devices such as spirometers and peak flow meters, monitoring devices like capnographs and pulse oximeters and therapeutic devices that include oxygen concentrators, nebulisers, Continuous Positive Airway Pressure (CPAP) devices, etc.  The growth in ASEAN and Oceania respiratory devices and diagnostics market is anticipated to accelerate in coming years due to an increase in prevalence of chronic respiratory diseases like Chronic Obstructive Pulmonary Diseases (COPD), asthma and Obstructive Sleep Apnea (OSA) in both aging as well as young population in this region. ASEAN, Oceania and other APAC cover Australia, Bangladesh, Indonesia, Malaysia, Myanmar, New Zealand, Philippines, Singapore, Thailand and Vietnam.

The prevalence of respiratory diseases, especially asthma, is very high in the Oceania region and it is increasing in ASEAN countries due to growing smoking habit, air pollution, aging population, unhealthy diet and physical inactivity leading to COPD and OSA. Due to the collective size of Indo-China market, ASEAN countries’ potential is underestimated. ASEAN is expected to boost growth in the APAC region. For instance, Indonesia is highly populated with considerable cases of chronic respiratory diseases and low treatment penetration rates. We are expecting penetration to improve with government initiatives like mobile community health services and government-financed health coverage program.

Respiratory devices are divided in to two segments—Homecare devices and Hospital care devices. Though, Hospital is a leading segment, the demand for Homecare devices is increasing for all products in the Oceania region while the demand is surging for low-value products such as nebulisers and peak flow meters along with related disposables in the ASEAN region.

The demand for disposable consumables has increased over reusable ones due to safety concerns, a decline in prices of consumables, an increase in disposable income and improving diagnostics facilities.

A large number of players attracted to the low entry barrier high volume nature of the ASEAN market, has made the market highly fragmented and unorganised. Hospitals prefer economical devices if scrap life of the device is short and replacement is more economical than repair. Economical disposables are preferred in the case of patients who are provided home care due to cost benefits. Hospitals prefer local or Chinese disposables due to higher margins compared with products from multi-national companies (MNCs).

The key players in this market are AirSep Corporation, a division of Chart Industries, CareFusion Corp (NYSE : CFN), Covidien plc, DeVilbiss Healthcare LLC, Fisher & Paykel Healthcare Corp Ltd (NZE : FPH), Invacare Corporation, Omron Healthcare, Inc., a division of Omron Corporation (6645: TSE), Philips Respironics, Inc., a division of Koninklijke Philips N.V. (AMS : PHIA, NYSE : PHG), ResMed Inc (NYSE: RMD).

ASEAN and Oceania Respiratory Devices and Diagnostics Market through 2020 - Detailed Analysis of Hospital and Retail market, a market report recently published by ABMRG, reviews historical trends and forecasts (between 2007 and 2020), annualised sales, market size (value and units), channel-wise revenue distribution for hospitals and retail, market growth, pricing, competitive landscape as well as overall and channel-wise market share.

It offers a proprietary cross-category comparison for products and geographies for the historical and forecast period. It also lists strategic developments in the global industry over the last two years, including M&As, partnerships, clinical studies, pipelines, product approvals and launches, recalls and litigations, market dynamics, market drivers and restraints.

Why one should buy this report 

The report can be instrumental in formulating strategic decisions to:

·         Make a business development strategy for the respiratory devices in ASEAN and Oceania region.

·         Frame a distribution strategy in the ASEAN and Oceania region based on a detailed analysis of hospitals and the retail channel market.

·         Launch competitive respiratory devices for individual countries.

·         Make capital investments based on the forecast for high potential markets.

·         Capitalize on opportunities in high-growth geographies and attractive respiratory devices markets.

·         Identify in-licensing and out-licensing opportunities, and spot potential business partners and M&A targets within the respiratory devices market.

·         Help respiratory devices
companies procure raw materials and inventory well in advance.

·         Prepare management and strategic presentations for investors and shareholders.

 

Other strategic market reports by ABMRG: 

-          Russia Oxygen Concentrators Market - Trends and Market Forecast 2019

http://www.abmrg.com/Russia-Oxygen-Concentrators-Market---Trends-and-Market-Forecast-2019.html

-          North America Respiratory Disposable and Anesthesia Disposable Device Market - Growth Trends and Potential 2006-2019

http://www.abmrg.com/North-America-Respiratory-Disposable-Device-Market-Trends-and-Potential-2006-2019.html

About ABMRG

ABMRG (Ace Business and Market Research Group) is a research and consulting firm focused on medical technology and pharmaceuticals. It offers comprehensive research and analytical studies targeting companies, therapeutic sectors and countries, highlighting market dynamics, vital trends, business strategies, clinical pipeline and technology advancements. Its cutting edge reports help companies make smarter, effective and faster strategic decisions for business growth. For detailed table of contents of  ASEAN and Oceania Respiratory Devices and Diagnostics Market Through 2021. contact

Contact:

Ankit Jian - sales@abmrg.com ; 19@abmrg.com

+91 – 8238155239; +91 - 261-2216406

 

Single User price :$13,007 Add To Cart
Enterprise Price :$14,006 Add To Cart
Global Corporate Price :$15,005 Add To Cart

 

India Coronary Stent and Angioplasty Market Through 2020 (Cath Lab Level Information—City, State and National)

-No one has covered cath labs in India like us: ABMRG

-Primary research covering 700 angioplasty centres in 150 cities

-Comparative analysis among states & regions; hospital chains; govt & pvt hospitals

http://www.abmrg.com/India-Coronary-Stent-and-Angioplasty-Market-Through-2020-Cath-lab-level-Information---City-State-and-National-.html

The coronary stent market in India, which comprises Drug Eluting Stent (DES), Bare Metal Stent (BMS) and Bio-Absorbable Stent (BVS), was valued above $400 million in 2012. DES accounts for bulk of sales in India. The bio-absorbable stent ABSORB has garnered a considerable traction despite its high cost compared with the other available DES. The key players operating in the segment are Alvimedica, Abbott Vascular, a division of Abbott Laboratories (NYSE : ABT), Boston Scientific (NYSE : BSX, LSE : BSX), Biosensors Inc., Biotronik, JW Medical, Medtronic, Inc. (NYSE :MDT), Meril Life Sciences, MicroPort Scientific Corporation (HKG: 0853), Sahajanand Medical Technologies and Translumina Therapeutics.

 

The market has grown impressively supported by a rise in coronary angioplasties which has resulted from a surge in cardiovascular diseases (CVDs), augmented healthcare spending as well as an increase in number of interventional cardiologists and cath labs in government and private hospitals, including individual cath lab centres run by interventional cardiologists as well as new corporate hospitals.

 

The demand has surged as central and state governments capped reimbursement rates which enhanced affordability resulting in an increase in volume. The decrease in reimbursement rates has given an edge to Indian, Asian and some of the Europe-based mid-sized MNCs which sell stents at almost half the price of those sold by US companies.

In the US, the stents market has slumped significantly due to negative results from clinical studies suggesting that one-third of stent implants are unnecessary. However, in India these studies have not made an impact as most Indian cardiologists do not seem to have taken these clinical outcomes seriously.

India Coronary Stent and Angioplasty Market Through 2020 (Cath Lab Level Information—City, State and National)’, is a market report published recently by ABMRG. It reviews historical trends and forecasts (between 2007 and 2020), annualised sales, market size (value and units), market growth, pricing, competitive landscape and market share.

The research report covers 700 cath labs across the country. It analyses angioplasty procedures’ (PCI and PTCA) data for the country with a detailed analysis at national, state, district, city and hospital levels. It provides PCI data of 550 hospitals from more than 150 cities. 

The report offers a proprietary cross-category comparison for products and geographies for the historical and forecast period. It also lists strategic developments in the global industry over the last two years, including M&As, partnerships, clinical studies, pipelines (R&D), product approvals and launches, recalls and litigations, market dynamics, market drivers and restraints.

Why one should buy this report - No one has covered cath labs in India like us.

The report can be instrumental in formulating strategic decisions to:

  • Make a regional strategy based on regional landscape and market characteristics.
  • Capitalise on opportunities in high-growth angioplasty regions/markets.
  • Plan capital investments based on the forecast for high angioplasty markets.
  • Prepare strategic presentations for the management, investors and shareholders.

Other strategic market reports: 

-          Global Coronary Stent Market Outlook Through 2019

http://www.abmrg.com/Global-Coronary-Stent-Market-Outlook-Through-2019.html

-          EU-7 Coronary Stents Market Outlook Through 2019

www.abmrg.com/EU-7-Coronary-Stents-Market-Outlook-Through-2019.html

-          European Interventional Cardiology Market through 2020

http://www.abmrg.com/European-Interventional-Cardiology-Market-through-2020.html

 

About ABMRG

ABMRG (Ace Business and Market Research Group) is a research and consulting firm focused on life sciences. It offers comprehensive research and analytical studies targeting various therapeutic sectors and its market dynamics, vital trends, business strategies and clinical pipeline. Its cutting edge reports empower companies to make smarter, effective and faster strategic decisions for business growth.

Contact:

Ankit Jian - sales@abmrg.com ; 19@abmrg.com

+91 – 8238155239; +91 - 261-2216406

Source: ABMRG

Single User price :$6,500 Add To Cart
Enterprise Price :$13,007 Add To Cart
Global Corporate Price :$18,506 Add To Cart

India Coronary Stent Market to be Tripled by 2021

-No one has covered cath labs in India like us: ABMRG

-Primary research covering 700 angioplasty centres in 150 cities

-Comparative analysis among states & regions; hospital chains; govt & pvt hospitals

http://www.abmrg.com/India-Coronary-Stent-and-Angioplasty-Market-Through-2020-Cath-lab-level-Information---City-State-and-National-.html

The coronary stent market in India, which comprises Drug Eluting Stent (DES), Bare Metal Stent (BMS) and Bio-Absorbable Stent (BVS), was valued above $400 million in 2012. DES accounts for bulk of sales in India. The bio-absorbable stent ABSORB has garnered a considerable traction despite its high cost compared with the other available DES. The key players operating in the segment are Alvimedica, 

Abbott Vascular, a division of Abbott Laboratories (NYSE : ABT), Boston Scientific (NYSE : BSX, LSE : BSX), Biosensors Inc., Biotronik, JW Medical, Medtronic, Inc. (NYSE :MDT), Meril Life Sciences, MicroPort Scientific Corporation (HKG: 0853), Sahajanand Medical Technologies and Translumina Therapeutics.

 

The market has grown impressively supported by a rise in coronary angioplasties which has resulted from a surge in cardiovascular diseases (CVDs), augmented healthcare spending as well as an increase in number of interventional cardiologists and cath labs in government and private hospitals, including individual cath lab centres run by interventional cardiologists as well as new corporate hospitals.

 

The demand has surged as central and state governments capped reimbursement rates which enhanced affordability resulting in an increase in volume. The decrease in reimbursement rates has given an edge to Indian, Asian and some of the Europe-based mid-sized MNCs which sell stents at almost half the price of those sold by US companies.

In the US, the stents market has slumped significantly due to negative results from clinical studies suggesting that one-third of stent implants are unnecessary. However, in India these studies have not made an impact as most Indian cardiologists do not seem to have taken these clinical outcomes seriously.

India Coronary Stent and Angioplasty Market Through 2020 (Cath Lab Level Information—City, State and National)’, is a market report published recently by ABMRG. It reviews historical trends and forecasts (between 2007 and 2020), annualised sales, market size (value and units), market growth, pricing, competitive landscape and market share.

The research report covers 700 cath labs across the country. It analyses angioplasty procedures’ (PCI and PTCA) data for the country with a detailed analysis at national, state, district, city and hospital levels. It provides PCI data of 550 hospitals from more than 150 cities. 

The report offers a proprietary cross-category comparison for products and geographies for the historical and forecast period. It also lists strategic developments in the global industry over the last two years, including M&As, partnerships, clinical studies, pipelines (R&D), product approvals and launches, recalls and litigations, market dynamics, market drivers and restraints.

Why one should buy this report - No one has covered cath labs in India like us.

The report can be instrumental in formulating strategic decisions to:

  • Make a regional strategy based on regional landscape and market characteristics.
  • Capitalise on opportunities in high-growth angioplasty regions/markets.
  • Plan capital investments based on the forecast for high angioplasty markets.
  • Prepare strategic presentations for the management, investors and shareholders.

Other strategic market reports: 

-          Global Coronary Stent Market Outlook Through 2019

http://www.abmrg.com/Global-Coronary-Stent-Market-Outlook-Through-2019.html

-          EU-7 Coronary Stents Market Outlook Through 2019

www.abmrg.com/EU-7-Coronary-Stents-Market-Outlook-Through-2019.html

-          European Interventional Cardiology Market through 2020

http://www.abmrg.com/European-Interventional-Cardiology-Market-through-2020.html

 

About ABMRG

ABMRG (Ace Business and Market Research Group) is a research and consulting firm focused on life sciences. It offers comprehensive research and analytical studies targeting various therapeutic sectors and its market dynamics, vital trends, business strategies and clinical pipeline. Its cutting edge reports empower companies to make smarter, effective and faster strategic decisions for business growth.

Contact:

Ankit Jian - sales@abmrg.com ; 19@abmrg.com

+91 – 8238155239; +91 - 261-2216406

Source: ABMRG

Indian Hospitals - Due Diligence Report   $4,700
  • Language: English | #Pages: 500 | Published: Apr-2015 | Region: Global
Single User price :$4,700 Add To Cart
Enterprise Price :$9,400 Add To Cart
Global Corporate Price :$18,800 Add To Cart

Indian Hospitals - Due Diligence Report

India Coronary Stents Market - Potential & Growth Forecast to 2019 (2nd Edition)   $13,834
  • Language: English | #Pages: 157 | Published: Feb-2015 | Region: Global
Single User price :$13,834 Add To Cart
Enterprise Price :$13,834 Add To Cart
Global Corporate Price :$13,834 Add To Cart

 India Coronary Stent Market Would Continue to Grow in Double Digits and Abbott Vascular  to Lead the Market 

The coronary stent market in India was valued around $450 million in 2012 and it has grown at an impressive rate of 22% (2005-2012) backed by a rise in PCIs (Percutaneous Coronary Intervention) which is resulted from a surge in cardiovascular disease (CVD), an improvement in healthcare infrastructure and services and an increase in disposable income. An increasing penetration of DES, which is above 90%, has also boosted the market.

The market is lead by Abbott Vascular, followed by Boston Scientific. Other key players operating in the segment are Medtronic, Inc., Biotronik, Sahajanand Medical Technologies, Meril Life Sciences and Translumina Therapeutics. Johnson and Johnson's Cordis stopped selling its stents from 20011. Cordis's market was grabbed by Abbott, Medtronic and other players. Bioabsorbable stent ABSORB, which was recently launched by Abbott Vascular, has garnered a considerable traction among the medical fraternity despite its high cost compared with other stents available in the market. The patients opting for ABSORB are financially sound or have either health insurance or are entitled for reimbursement. Abbott is aggressively chasing the market through a direct-to-consumer approach (DTC).
 
The coronary stent market in the country will continue to grow at a faster pace due to new and upcoming private hospitals, government initiatives to improve healthcare access, an increasing number of interventional cardiologists, an explosion of healthcare insurance and a growth in usage of high value bioabsorbable stents. The anticipated progression can be attributed to growth in elderly population, improved life expectancy, lifestyle diseases and associated complications like diabetes, hypertension and obesity.
 
The majority of population in need of stents is not covered under health insurance or do not get reimbursements which limits the market. However, patients under the poverty line are sponsored for healthcare insurance through the state government or insurance under public and private partnership. Some state governments have put a cap on the pricing of stents; though it may limit the market in terms of value but may help increase penetration of stents. Some state governments have put a cap on the value of stents; though this may help increase penetration of stents, it may limit the market in terms of value.
Meanwhile, the market is crowded with local players. Also, Europe-based mid-sized companies sell stents at almost half the price of international brands. It makes the market more competitive for MNCs. Further, the reduction in the reimbursement rates under the Central Government Health Scheme (CGHS) is likely to force companies to lower prices in the market.  
 
However, the main restraints to market growth are high device and procedure costs and a lack of skilled interventional cardiologists. Hospitals and distributors in the supply chain make a killing as the device is mostly used in patients for emergency treatment.
The recently published strategic market report by ABMRG, "India coronary stent market-potential and growth forecast to 2019", analyzes the coronary stent market in India. It reviews historical trends and forecasts (2005-2019) the annualized trends for sales in terms of value and volume, market growth, pricing (Average Selling Price or ASP), competitive landscape and market share. It outlines coronary pipeline products and highlights findings of the global clinical studies. It offers a cross-category comparison for the historical and forecast period. It also provides global industry developments for the last two years, including M&As, partnerships, clinical studies, pipeline, product approvals and launches, recalls and litigations, market dynamics and market drivers.
BRICS Hearing Aids, Implants and Diagnostic Market Through 2020   $5,005
  • Language: English | #Pages: 150 | Published: Dec-2014 | Region: Global
Single User price :$5,005 Add To Cart
Enterprise Price :$10,010 Add To Cart
Global Corporate Price :$15,015 Add To Cart

The BRICS Hearing Aids, Hearing Implants and Hearing Diagnostic market has witnessed a substantial growth of 4.8 per cent in last few years and it is likely to register higher growth than expected. This could be attributed to the continuous innovation and technological advancements in the designs of hearing aids and implants, resulting in improved acceptability among patients. Further, the emerging economies of BRICS, with constantly improving healthcare infrastructure, growing population, rapid urbanization and unmet medical needs, offer a huge, untapped growth potential and lucrative market opportunities.

China and India account for around 36.8 per cent of the world's population and collectively housing nearly 31.3 per cent of the world's elderly population, and have consequently become a home for a large hearing-impaired patient base. With growing economies and rapid urbanization, BRICS represents a high-potential market after the US for hearing aids devices.

The BRICS comprises emerging economies which account for one-fifth of world GDP. The BRICS market is primarily driven by factors such as significant aging population, increasing awareness, improved diagnosis rates and rising affordability. While, the BRICS market relies on imports from foreign firms, the introduction of advancements such as wireless devices and features such as Bluetooth as well as aesthetic designs have brought in a transition towards more refined devices in the market. On the other hand, high cost of these devices and limited reimbursement remain to be key restraints curtailing the market.

In order to overcome pricing pressure, companies are continuously introducing new designs and technologies which have helped sustain the overall growth of the market. Further better patient compliance rendered by these products, evolution of digital technology, cosmetically attractive designs of devices which are not visible outwardly and enhanced connectivity has augmented the acceptability and usage of hearing devices. Hence, the potential of conversion to binaural devices and replacement of existing ones with the help of new technology are likely to drive the growth of the hearing aids market.

The key players dominating the hearing aids space are Envoy Medical Corporation, GN ReSound A/S, Istok-Audio, Siemens Healthcare (SIE:XETRA), Sonova Holding AG (SIX), Starkey Hearing Technologies, Inc., RION Co., Ltd (TSE:6823), Widex A/S and William Demant Holding A/S (WDH.F).

'BRICS Hearing Aids, Implants and Diagnostic Market Through 2020', a strategic market report published by ABMRG recently, analyzes the hearing aids, implants and diagnostics market for the entire BRICS region (Brazil, Russia, India, China, and South Africa). It reviews historical trends and forecasts (for the period from 2007 to 2020), annualized trends for sales in terms of value and volume, market growth, pricing (Average Selling Price or ASP), competitive landscape and market share. It outlines the hearing aids and implants pipeline products and highlights findings of global clinical studies. It offers a cross-category comparison for the historical and forecast period. It also lists developments in the global industry over the last two years, including M&As, partnerships, clinical studies, pipelines, product approvals and launches, recalls and litigations, market dynamics, market drivers and restrains.

 

Why one should buy this report 

The report can be instrumental in making strategic decisions pertaining to:

  • Launch of competitive hearing aids and implants products in the BRICS region.
  • Capital investments based on the forecast for high potential hearing aid, hearing implants and hearing diagnostic segments.
  • Capitalization of opportunities in high-growth geographies and attractive hearing aids and hearing implants markets.
  • Identification of in-licensing and out-licensing opportunities, and recognizing potential business partners and M&A targets within the hearing aids market.
  • Procurement of raw material and inventory well in advance for the hearing equipment companies.
  • Preparation of management and strategic presentations for the investors and shareholders.
  • Managerial presentations to the management.

 

Opportunities For Composites In Orthopedic Applications: 2014-2020   $2,800
  • Language: English | #Pages: 47 | Published: Dec-2014 | Region: Global
Single User price :$2,800 Add To Cart
Enterprise Price :$5,600 Add To Cart
Global Corporate Price :$8,400 Add To Cart

Composites in global orthopedic industry are expected to grow at an average rate of 8.1%. The US has highest consumption in terms of value and volume. Hip, knee and spine surgeries are the common orthopedic procedures in the developed world while in emerging economies they have a lower penetration. Increased number of product recalls and failure rates are challenging the use of composites. Non-metallic orthopedic devices have gained popularity in the industry as they offer reduced failures, light weight, and last longer than their metallic counterparts.

‘Opportunities for Composites in Orthopedic Applications: 2014-2020’, a strategic market report published by ABMRG recently, provides a comprehensive analysis of the global composites in orthopedic market. The global market for composites in orthopedic industry has been studied from various perspectives. The study includes the current market, trends (2007-2013) and forecasts (2014-2020) for composite materials in orthopedic industry. The report tracks the market by fixture type, raw materials used, applications, and geographic regions. It also provides statistical analysis in terms of value ($ million) and volume (million tons). The study also highlights the trends, unmet needs, drivers, and restrains affecting the use of composites in orthopedic industry.

Aging population and rising living standards have enhanced the growth of the orthopedic industry. A reduction in curing time, along with an increase in performance of these devices, has necessitated the need for innovation for new materials. “The future market will be challenged by emerging materials, technologies, applications, and procedures. Strong learning curve and experience of the metallic substitutes also challenge the growth of composites in the orthopedic industry”, said ABMRG analyst Purva Jain.

The composites market for global orthopedic industry is segmented as follows:

By Application

      -  Hips

      -  Knees

      -  Spine

      -  Trauma

      -  Sports

      -  Dental

      -  Others 

By Fixture Type

      -  Implants

      -  External Fixation Devices

By Raw Materials

      -  Fiber

      -  Resin

By Geographic Region

      -  The US 

      -  Europe

      -  APAC and MEA

The study also analyses the competition among the key players and illustrates their market shares for 2013. Major players in the industry include Arthrex Inc., DJO Global Inc. (DJO, LLC), Invibio, Johnson & Johnson (NYSE: JNJ), Medtronic, Inc. (NYSE: MDT), NuVasive, Inc. (NASDAQ: NUVA), Orchid Orthopedic, Paragon Medical, Smith & Nephew plc (LSE: SN) and Stryker Corporation (NYSE: SYK). 

 
Global Mammography Systems Market Forecast and Opportunity Assessment, 2007 - 2020   $7,300
  • Language: English | #Pages: 136 | Published: Dec-2014 | Region: Global
Single User price :$7,300 Add To Cart
Enterprise Price :$14,600 Add To Cart
Global Corporate Price :$21,900 Add To Cart

Breast cancer, one of the most common types of cancer affecting women worldwide, represents about a quarter of all cancer deaths in women. This high mortality indicates the unmet needs of patients diagnosed with breast cancer and has resulted in a surge in demand for mammography devices in developing countries and upgrade or replacement to digital mammography systems, Full Field Digital Mammography (FFDM) and 3-D mammography systems from analogue mammography systems in developed nations. This has enhanced the growth of the global mammography market which is projected to be $2.8 billion by 2020.

 Also, the acceptance of early diagnosis has increased among people as a result of enhanced breast cancer awareness, initiation of breast screening programs, evolution in technologies and steps to improve reimbursement policies by various governments. Yet factors like high risk of exposure to radiation, false diagnosis, uncomfortable procedure, risk of occurrence of interval cancer and lack of female technicians are restraining the market growth.

Among mammography systems, digital mammography has the largest market in the US, EuropeAustralia and Japan but it is relatively a newer technology for the underpenetrated markets for mammography, like the rest of the Asia Pacific. For the rest of APAC and other developing economies, FFDM systems would become major centers of growth in the longer run.

The leading player in this segment is Hologic, Inc. (Nasdaq: HOLX) with considerable share in the global mammography systems market in 2013. The other key players in this space are Carestream Health, Esaote, FUJIFILM Holdings Corp. (TSE: 4901), GE Healthcare, Hitachi, Ltd. (TSE: 6501), Internazionale Medico Scientifica Srl., Mindray Medical International Limited (FRA: G2N), PerkinElmer Inc. (NYSE: PKI), Philips Healthcare (AMS: PHIA), Planmed Oy, Sectra AB, Shimadzu Corp. (TSE: 7701), Siemens Healthcare, SonoCine, Inc. and Toshiba Medical Systems Corp. (TSE: 6502).

'Global Mammography Systems Market Forecast and Opportunity Assessment, 2007-2020', a strategic market report published by ABMRG recently, provides a comprehensive analysis of the global mammography market covering regions like the US,Europe and APAC. It puts forth a detailed overview of historical trends and forecasts (2007-2020) as well as the annualized trends for sales in terms of value and volume, market growth, pricing (Average Selling Price-ASP), competitive landscape and market share. It also offers a cross-category comparison for the historical and forecast period, market drivers, market restrains and challenges. In addition, it presents an inclusive account of global industry developments for the past two years, including M&As, partnerships, clinical studies, pipeline, product approvals and launches, recalls and litigations.

Why one should buy this report 

The report can be instrumental in strategic decision making pertaining to:

  • Competitive mammography system launches - global or regional or individual countries.
  • Capital investments based on the forecast for high potential mammography system.
  • Capitalization of opportunities in high-growth geographies and attractive mammography markets.
  • Identification of in-licensing and out-licensing opportunities, and recognizing potential business partners and M&A targets within the mammography market.
  • Procurement of raw material and inventory well in advance for the mammography system companies.
  • Preparation of management and strategic presentations for investors and shareholders.
  • Managerial presentations to the management.
  • This report is an essential source for in-depth information and data relating to the global mammography market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information.
APAC Joint Replacement And Joint Reconstruction Market Through 2020   $7,309
  • Language: English | #Pages: 109 | Published: Dec-2014 | Region: Global
Single User price :$7,309 Add To Cart
Enterprise Price :$14,618 Add To Cart
Global Corporate Price :$21,927 Add To Cart

The Joint Replacement and Joint Reconstruction Market, comprising hip replacement, knee replacement, shoulder replacement and small joint replacement, in the Asia Pacific (APAC)is projected to reach $6.4 billion by 2020. Hip arthroplasty and knee arthroplasty are the most common types of joint replacements in APAC.

Currently, the growth in the region is driven by chronic medical conditions such as osteoarthritis, rheumatoid arthritis and osteoporosis; technical advancement in implant designs; new joint biomaterials; and robotic and minimally invasive surgeries (MIS). Also, the market is pushed by favorable macroeconomic factors, especially in India and China.

The future growth would be driven by the above-mentioned chronic conditions, younger patients undergoing joint replacement and requiring further revision surgeries during their lifetime. The market's growth would also be fuelled by improved healthcare infrastructure, better diagnosis facilities, and favorable macro economic factors such as increasing disposable income and rising healthcare expenditure.

Also, a decline in sales and pricing pressure in the US and other developed markets has forced companies to increase their focus on the APAC region. China and India offer a huge potential for market growth due to their developing economies and the size of the population. The key attributes that will govern the market in this region will be innovation, technology, reduced cost and existing products that are refined.

The key players dominating this space are DePuy Medical Pty. Ltd, a Johnson & Johnson Company(JNJ), Smith & Nephew plc (NYSE: SNN; LSE: SN), Stryker Corporation(SYK) and Zimmer Holdings Inc (ZMH). Other players in this space are Implants International Ltd., KYOCERA Medical Corporation, subsidiary of Kyocera Corp. (NYSE: KYO; TSE: 6971), Japan Medical Dynamic Marketing, Inc. (TSE:7600), Mathys Medical, OMNI Life Science, a subsidiary of Orthopaedic Synergy, Inc., Waldemar LINK and Wright Medical Group, Inc. (WMGI).

'APAC Joint Replacement And Joint Reconstruction Market Through 2020', a strategic market report published by ABMRG recently, analyzes the joint replacement market for the entire APAC region. It reviews historical trends and forecasts (for the period from 2007 to 2020), annualized trends for sales in terms of value and volume, market growth, pricing (Average Selling Price or ASP), competitive landscape and market share. It outlines the joint replacement pipeline products and highlights findings of global clinical studies. It offers a cross-category comparison for the historical and forecast period. It also lists developments in the global industry over the last two years, including M&As, partnerships, clinical studies, pipelines, product approvals and launches, recalls and litigations, market dynamics, market drivers and restrains.

Why one should buy this report 

The report can be instrumental in making strategic decisions pertaining to:

  • Competitive orthopedic product launches in APAC or countries within the region.
  • Capital investments based on the forecast for high potential joint replacement segments.
  • Capitalization of opportunities in high-growth geographies and attractive joint arthroplasty markets.
  • Identification of in-licensing and out-licensing opportunities, and recognizing potential business partners and M&A targets within the joint market.
  • Procurement of raw material and inventory well in advance for the orthopedic equipment companies.
  • Preparation of management and strategic presentations for the investors and shareholders.
  • Managerial presentations to the management.

 1    2   | 3   | 4   | 5   | >   | >>   

Page 1 of 230   showing records 1 to 10 of 2292 in this selection